Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up – Time to Buy?

Capricor Therapeutics, Inc. (NASDAQ:CAPR – Get Free Report)’s stock price gapped up prior to trading on Tuesday. The stock had previously closed at $8.30, but opened at $8.71. Capricor Therapeutics shares last traded at $8.81, with a volume of 1,964,773 shares trading hands.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CAPR. Ladenburg Thalmann & Co. Inc. lowered Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, July 30th. Alliance Global Partners downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price on the stock. in a research note on Tuesday, July 28th. Roth Capital reiterated a “neutral” rating and set a $10.50 price target (up from $7.00) on shares of Capricor Therapeutics in a research report on Friday. Piper Sandler raised shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Tuesday, September 1st. Finally, JonesTrading raised shares of Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Wednesday, November 11th. Five analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $30.09.

Get Our Latest Stock Report on CAPR

Capricor Therapeutics Stock Performance

The stock has a market cap of $498.86 million, a price-to-earnings ratio of -3.25 and a beta of 0.80. The company has a 50-day simple moving average of $8.08 and a two-hundred day simple moving average of $19.79.

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.29). As a group, sell-side analysts predict that Capricor Therapeutics, Inc. will post -2.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. RA Capital Management L.P. lifted its stake in shares of Capricor Therapeutics by 99.9% in the third quarter. RA Capital Management L.P. now owns 3,014,183 shares of the biotechnology company’s stock worth $28,544,000 after acquiring an additional 1,506,339 shares during the period. Entropy Technologies LP bought a new position in shares of Capricor Therapeutics in the 3rd quarter worth $343,000. Jump Financial LLC increased its position in shares of Capricor Therapeutics by 1,984.9% during the third quarter. Jump Financial LLC now owns 480,286 shares of the biotechnology company’s stock worth $4,548,000 after acquiring an additional 457,250 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Capricor Therapeutics by 21.2% in the third quarter. Russell Investments Group Ltd. now owns 17,326 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 3,036 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its stake in shares of Capricor Therapeutics by 151.7% in the 3rd quarter. Commonwealth Equity Services LLC now owns 67,402 shares of the biotechnology company’s stock worth $638,000 after acquiring an additional 40,627 shares in the last quarter. 21.68% of the stock is owned by institutional investors.

About Capricor Therapeutics

(Get Free Report)

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.

See Also

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.